Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China
- Sunday, October 16, 2022, 7:14
- PR Newswire
- Add a comment
SUZHOU, China, Oct. 16, 2022 /PRNewswire/ — Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients…
About the Author
admin has written 20655 stories on this site.